{"id":"W4385217389","doi":"10.1158/1535-7163.mct-23-0065","title":"First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Adaptive Biotechnologies; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Anemia; Gastroenterology; Mucositis; Neutropenia; Combination therapy; Refractory (planetary science); Pharmacokinetics; Olaparib; Cancer; Diarrhea; Toxicity; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000192349,0.0002260997,0.0003146899,0.0002087691,0.00004122796,0.00001100128,0.0001808796,0.0001292504,0.000003712933],"category_scores_gemma":[0.00001485123,0.0002073367,0.00004820041,0.0004124076,0.0001090931,0.000007256031,0.0001175552,0.00008999601,4.645682e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004753986,"about_ca_system_score_gemma":0.0001013321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002409429,"about_ca_topic_score_gemma":0.0006404526,"domain_scores_codex":[0.9984354,0.0001368315,0.0004662834,0.0004072187,0.0002744184,0.0002798983],"domain_scores_gemma":[0.999226,0.000006836539,0.0002288352,0.0003815083,0.0001018977,0.00005495155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005980711,0.001455745,0.09864867,0.000134734,0.0001392646,0.00003462676,0.0007128316,0.0003211971,0.8962984,0.00003964488,0.000009799211,0.001607038],"study_design_scores_gemma":[0.008023286,0.003260063,0.1117804,0.0003032574,0.00003333148,8.971246e-7,0.0004060696,0.0001340428,0.8754146,0.00005161001,0.0002361254,0.0003562839],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983287,0.000360783,0.0000528419,0.00004189926,0.00003412172,0.001117436,0.00001990287,0.00001168826,0.00003262985],"genre_scores_gemma":[0.9994721,0.00004107964,0.00008545069,0.00007018939,0.0000163418,0.0001753765,0.00003905707,0.0000494161,0.00005103397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02088375,"threshold_uncertainty_score":0.8454944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0121741033571396,"score_gpt":0.249141873966883,"score_spread":0.2369677706097434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}